Emerging cardiac MRI biomarkers such as T1/T2 mapping and strain imaging allow for earlier detection of cardiomyopathy in Duchenne muscular dystrophy, potentially improving clinical care and therapeutic evaluation.
May aid earlier DMD cardiomyopathy detection; hypothesis-generating and requires prospective validation before practice change.
Duchenne muscular dystrophy (DMD) is a fatal inherited genetic disorder that results in progressive muscle weakness and ultimately loss of ambulation, respiratory failure and heart failure. Cardiac MRI (MRI) plays an increasingly important role in the diagnosis and clinical care of boys with DMD and associated cardiomyopathies. Conventional cardiac MRI biomarkers permit measurements of global cardiac function and presence of fibrosis, but changes in these measures are late manifestations. Emerging MRI biomarkers of myocardial function and structure include the estimation of rotational mechanics and regional strain using MRI tagging; T1-mapping; and T2-mapping, a marker of inflammation, edema and fat. These emerging biomarkers provide earlier insights into cardiac involvement in DMD, improving patient care and aiding the evaluation of emerging therapies.
No takes yet. Share an insight, caveat, or question.
Magrath et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: